Editing Dimethyltryptamine (section)

==Interactions==
{{See also|Psychedelic drug#Interactions|Trip killer#Serotonergic psychedelic antidotes}}

DMT is inactive when ingested orally due to metabolism by [[Monoamine_oxidase|MAO]], and DMT-containing drinks such as ayahuasca have been found to contain [[monoamine oxidase inhibitors|MAOI]]s, in particular, [[harmine]] and [[harmaline]].<ref name="pmid11292011" /> Life-threatening lethalities such as [[serotonin syndrome]] (SS) may occur when MAOIs are combined with certain [[Serotonin|serotonergic]] medications such as [[SSRI]] antidepressants.<ref name="pmid9924842" /><ref name="pmid29366418" /> Serotonin syndrome has also been reported with [[tricyclic antidepressant]]s, opiates, [[analgesic]], and [[antimigraine drug]]s; it is advised to exercise caution when an individual had used [[dextromethorphan]] (DXM), [[MDMA]], [[ginseng]], or ''[[Hypericum perforatum|St. John's wort]]'' recently.<ref name="pmid29366418" />

Chronic use of SSRIs, [[Tricyclic_antidepressant|TCA]]s, and MAOIs diminish subjective effects of psychedelics due to presumed SSRI-induced 5-HT<sub>2A</sub> receptors downregulation and MAOI-induced 5-HT<sub>2A</sub> receptor desensitization.<ref name="9780192678522-drug-interaction">{{cite book | title = Psychedelics as Psychiatric Medications | publisher = [[Oxford University Press]] | url = https://books.google.com/books?id=7lazEAAAQBAJ | date = 7 March 2023 | vauthors = David N, David C | isbn = 978-0-19-267852-2 | chapter = Drug-interaction with psychotropic drugs | access-date = 21 May 2023 | archive-date = 21 May 2023 | archive-url = https://web.archive.org/web/20230521000115/https://books.google.com/books?id=7lazEAAAQBAJ | url-status = live }}</ref>{{rp|145}} However, a clinical study of people with [[depression (mood)|depression]] found that [[selective serotonin reuptake inhibitor]]s (SSRIs) did not diminish the effects of DMT and instead resulted in greater [[mystical experience]], [[emotional breakthrough]], and [[ego dissolution]] scores with DMT than in people with depression not on [[antidepressant]]s.<ref name="JamesJoelAttwooll2024">{{cite journal | vauthors = James E, Joel Z, Attwooll V, Benway T, Good M, Tziras G, Routledge C, Macek T | title=ACNP 63rd Annual Meeting: Poster Abstracts P1-P304: P160. SPL026 (DMT Fumarate) in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs) for Patients With Major Depressive Disorder | journal=Neuropsychopharmacology | volume=49 | issue=S1 | date=2024 | issn=0893-133X | pmid=39643633 | pmc=11627186 | doi=10.1038/s41386-024-02011-0 | doi-access=free | pages=65–235 (155–156) | url=https://www.nature.com/articles/s41386-024-02011-0.pdf | access-date=31 January 2025}}</ref> This was in contrast to previous research finding that SSRIs diminished the effects of serotonergic psychedelics.<ref name="HalmanKongSarris2024">{{Cite journal |vauthors=Halman A, Kong G, Sarris J, Perkins D |date=January 2024 |title=Drug-drug interactions involving classic psychedelics: A systematic review |journal=J Psychopharmacol |volume=38 |issue=1 |pages=3–18 |doi=10.1177/02698811231211219 |pmc=10851641 |pmid=37982394}}</ref> The interaction between psychedelics and [[antipsychotic]]s and [[anticonvulsant]] are not well documented, however reports reveal that co-use of psychedelics with [[mood stabilizer]]s such as [[Lithium_(medication)|lithium]] may provoke [[seizure]] and [[Dissociative_disorder|dissociative effects]] in individuals with [[bipolar disorder]].<ref>{{cite journal | journal = Drug and Alcohol Dependence | doi = 10.1016/j.drugalcdep.2022.109586 | volume = 239 | date = 1 October 2022 | vauthors = Otto S, Simon G, Richard C, Walter O, Distin L, Peter H | pmid = 35981469 | pmc = 9627432 | title = Prevalence and associations of classic psychedelic-related seizures in a population-based sample| page = 109586 }}</ref><ref name="9780192678522-drug-interaction" />{{rp|146}}